This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
Questions about our CME?
Questions about our CME?

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

ExpertPerspectives: Advancing Knowledge to Practice: Optimizing Severe Asthma Care in the Age of Biologics

ExpertPerspectives: Advancing Knowledge to Practice: Optimizing Severe Asthma Care in the Age of Biologics

Format

Webcast

Time to Complete

1 hour

Released

December 31, 2018

Expires

December 30, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour
1.00 / AANP Contact Hour
1.00 / CE for Pharmacists (0.10 CEUs)

Accredited Provider

Provided by the Annenberg Center for Health Sciences at Eisenhower

Commercial Supporter

This activity is supported by educational grants from GlaxoSmithKline, AstraZeneca, Sanofi Genzyme and Regeneron Pharmaceuticals.

Program Description

Michael E. Wechsler, MD and Jonathan Corren, MD, discuss the clinical differentiation of asthma subgroups and the characterization of inflammatory pathways, as well as biomarkers for severe asthma and their application to clinical practice. They review the latest treatment options, focusing on new biologic-based targeted therapies, differentiating between biologic agents and their mechanism of action, as well as the latest safety and efficacy data of targeted therapy. They also discuss optimal treatment regimens based on asthma severity and biomarkers.

Intended Audience

Pulmonologists, allergists, pulmonology nurses, nurse practitioners, fellows, residents, and other clinicians involved in the management of severe asthma

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Explain how phenotypic, endotypic, and other genetic characteristics factor into severe asthma
  • Compare and contrast biological agents that are currently available or emerging in the treatment of severe asthma
  • Identify patients who may benefit from the use of a biological agent for severe asthma
  • Employ a stepwise approach to incorporating novel, personalized biologic-based treatment plans for severe asthma into the real-world clinical setting

Conflict Of Interest Disclosure Policy

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Faculty

Jonathan Corren, MD
Clinical Associate Professor of Medicine and Pediatrics
Divisions of Clinical Immunology and Allergy
David Geffen School of Medicine at UCLA
Los Angeles, California

Dr. Corren discloses the following:
Research Support: AstraZeneca-clinical area: Asthma; Genentech-clinical area: Asthma; Regeneron-clinical area: Asthma; Sanofi-clinical area: Asthma; Stallergenes Greer-clinical area: Allergic rhinitis.
Consultant: Genentech-clinical area: Asthma; Novartis-clinical area: Asthma; Regeneron-clinical area: Asthma; Sanofi-clinical area: Asthma
Speakers Bureau: AstraZeneca-clinical area: Asthma; Genentech-clinical area: Asthma; Novartis-clinical area: Asthma

Michael Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado

Dr. Wechsler discloses the following:
Research Support: AstraZeneca-clinical area: Asthma; Novartis-clinical area: Asthma; Sanofi-clinical area: Asthma
Consultant: AstraZeneca-clinical area: Asthma; Boehringer Ingelheim-clinical area: Asthma; Novartis-clinical area: Asthma; GlaxoSmithKline-clinical area: Asthma; Sanofi-clinical area: Asthma; Teva-clinical area: Asthma; Regeneron-clinical area: Asthma

Publishing Staff Disclosures

Additional content planners
Victoria Anderson (medical writer) has nothing to disclose.
Eugene Cullen, MD (peer reviewer) has nothing to disclose.
Heather Jimenez, FNP (lead nurse planner) has nothing to disclose.

Annenberg Center for Health Sciences
All the staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation Statement

A maximum of 1.00 contact hour may be earned for successful completion of this activity.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.00 contact hour. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Credit

1.00

Type

CE for Nurse Practitioners

Accreditation Statement


Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.

Designation Statement

This program is accredited for 1.00 contact hour. Program ID #5664-EM.

Credit

1.00

Type

CE for Pharmacists

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-0000-18-208-H01-P. This program is designated for up to 1.00 contact hour (0.10 CEU) of continuing pharmacy education credit.

Transcript information will be available at www.mycpemonitor.net within 4 weeks.

Disclosure of Unlabeled Use

The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved indications.

Disclaimer

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Instructions

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications for your practice, and completing the assessment component.

Please note: The content of this activity is housed on the website of our educational partner, Annenberg Center for Health Sciences at Eisenhower, and requires you to leave myCME and register on the Annenberg website.

Your certificate will be saved on the Annenberg website only and cannot be accessed in your myCME CME History. Please go to https://education.annenberg.net and sign in to access your certificate in the future.

Contact Information

For help or questions about this Internet activity, please contact Annenberg Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone: 760-773-4500
Fax: 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Privacy Policy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/

myCME privacy policy
Add to Queue